Pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced preliminary long-term data from a late-stage extension trial of its muscarinic antipsychotic drug KarXT (xanomeline + trospium) in adult patients with schizophrenia. The 52-week study demonstrated significant improvements, with participants showing an average reduction of 34% in the positive and negative syndrome scale (PANSS) total score and a mean improvement of 33% in the clinical global impression-severity (CGI-S) score. Notably, the long-term benefits were found to be comparable for patients who had received KarXT or placebo during the prior Phase III trials.
The safety profile of KarXT was consistent with earlier trials, and the drug also showed additional benefits, including positively impacting weight and stabilizing or improving metabolic parameters, which are critical factors in the treatment of schizophrenia.
Bristol Myers Squibb, which has been focusing on delivering innovative therapies for serious diseases, plans to publish further data on KarXT later this year, potentially strengthening the drug’s profile for regulatory submissions and commercialization.- Flcube.com
